A Randomized Phase III Trial of S-1/Oxaliplatin (SOX) plus Bevacizumab versus 5-FU/l-LV/Oxaliplatin (FOLFOX) plus Bevacizmab in Treating Patients with Metastatic Colorectal Cancer.

Trial Profile

A Randomized Phase III Trial of S-1/Oxaliplatin (SOX) plus Bevacizumab versus 5-FU/l-LV/Oxaliplatin (FOLFOX) plus Bevacizmab in Treating Patients with Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SOFT
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 03 Jul 2014 Status changed from active, no longer recruiting to completed.
    • 30 May 2014 Results from final analysis presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 13 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top